– Preclinical data supports the potential of the unique nsCAR platform to selectively eliminate cancer cells while preserving healthy tissue
– Gamma delta nsCAR platform emerges as an advanced technology targeting blood and solid cancers
NEW YORK, April 9, 2024 (GLOBE NEWSWIRE) — IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma delta T-cell therapies, announced today that announced new preclinical data. A T cell-based chimeric antigen receptor T cell (nsCAR) platform known as INB-300 has demonstrated improved selectivity for target leukemic cells while preserving healthy leukemic cells. This data supports the possibility that nsCAR has a broader therapeutic range and can be used to prevent off-target tumor killing in healthy tissues that may express CAR-T targets. This data was presented in a poster session at the American Association for Cancer Research (AACR) 2024 Annual Meeting on April 9, 2024.
IN8bio's nsCAR platform is based on the natural ability of gamma delta T cells to differentiate between healthy and malignant tissue. By using chimeric antigen receptors (CARs) lacking signaling domains, IN8bio has developed a technology that allows these cells to distinguish between tumor and healthy tissues even when both express the CAR target antigen. I think I did.
Approved CAR-T therapies have shown significant efficacy against B-cell malignancies, offering hope to patients with limited treatment options. However, extending this therapy to myeloid malignancies and solid tumors has proven difficult because the antigens they target are often also present on the surface of healthy blood cells and tissues. I am. Unintentional targeting of healthy cells and tissues has resulted in many of the toxicities, including patient death, observed with previous CAR-T therapies, limiting their usefulness. Unlike traditional CAR-T therapies, IN8Bio's nsCAR is designed to target gamma delta T cells while preserving their own gamma delta T cell receptors, targeting tumor-associated stress antigens. Through this recognition, foreign tumor cells can be identified and specifically eliminated. .
New data presented at AACR included results from unique constructs targeting CD33 and/or CD123. in vitro Evaluation of different types of leukemia, including acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). Study results demonstrated significant differences between cells expressing conventional signaling CARs and cells expressing nsCAR constructs, including reduced activation-induced cell death by the nsCAR constructs.
nsIL3-33mb15 CAR (CD123+CD33+IL-15) enhancement of gamma delta T cells against leukemia cells showed average tumor killing ability across three AML cell lines (HL-60, KG-1a, and MOLM-15) showed a 1.8-fold increase. 13), compared to unmodified gamma delta T cells measured in a 24-hour cytotoxicity assay. Importantly, nsCAR cells did not significantly kill healthy cells expressing CD33 or CD123 targets, demonstrating the selectivity of the nsCAR platform. The results were performed three times and on average the selectivity increased by a factor of 5.5. In all experiments, killing of healthy CD34+ HPCs by the nsIL3-33mb15 construct was lower than that of untransduced control gamma delta T cells.
“INB-300 can selectively target leukemic cells while preserving healthy tissue. We are currently conducting further optimizations to improve the integration of membrane-bound IL-15 co-expression. Dr. Lawrence Lam said: ., Co-Founder and Chief Scientific Officer of IN8bio. “These results may improve INB-300 as we move toward an IND that will enable research into next-generation gamma delta T cell therapies for cancer treatment.”
About INB-300
INB-300 is an nsCAR gamma delta T cell platform with several preclinical product candidates, including the INB-330 program for AML targets, which combines our expertise in gamma delta T cells and genetic engineering. These nsCAR constructs lack signaling domains to exploit the unique properties of gamma delta T cells to differentiate between healthy and tumor tissues. IN8bio is developing novel nsCAR constructs against multiple targets to treat both solid and liquid tumors.
About IN8bio
IN8bio is a clinical-stage biopharmaceutical company developing gamma delta T cell-based immunotherapies for cancer patients. Gamma delta T cells are a specialized T cell population with unique properties, including the ability to distinguish between healthy and diseased tissue. His INB-400, the company's flagship program, is in Phase 2 trials for glioblastoma multiforme (GBM). Additional programs include Phase 1 trials in solid tumors and hematologic malignancies, including INB-200 for GBM and INB-100 for patients with hematologic malignancies undergoing transplantation. For more information about IN8bio, please visit www.IN8bio.com.
Forward-looking statements
This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “goal,” “anticipate,” “believe,” and “potential.” “estimate”, “expect”, “predict”, “goal”, “intend”, “may”, “plan”, “could”, “could”, ” “seeks,” “anticipates,” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements include these words. Not. Forward-looking statements in this press release include the ability of IN8bio's nsCAR platform to (i) selectively target and eradicate cancer cells while preserving healthy tissue through recognition of tumor-associated stress antigens; (ii) have a broader therapeutic range and are used to prevent off-target tumor killing of healthy tissues that may express CAR-T targets; IN8bio's ability to enhance both the efficacy and safety of next-generation adoptive cell therapies for a broader range of cancers. and IN8bio's ability to advance its pipeline of novel gamma delta CAR-T therapies to treat additional cancers, including both solid and liquid tumors. You should not place undue reliance on these forward-looking statements, as IN8bio may not actually be able to achieve the plans, intentions or expectations disclosed in these forward-looking statements. Actual results or events may differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of a variety of factors, including: uncertainties inherent in the initiation and completion of preclinical studies, clinical trials, and clinical development of IN8bio products, including patient enrollment and follow-up and IN8bio's ability to meet expected deadlines and milestones; It will be. the risk that IN8bio may not realize the intended benefits of her DeltEx platform; availability and timing of preclinical research and clinical trial results; Whether the results of preclinical studies predict the results of clinical trials. Whether the initial or interim results of a clinical trial predict the final results of that trial or the results of future trials. Risk that clinical trials and research may be delayed and results may not be satisfactory. potential adverse effects arising from testing or use of IN8bio's product candidates; uncertainties related to regulatory approvals to conduct clinical trials or market products; IN8bio relies on third parties, including licensors and clinical research institutions. and other important factors could cause our actual results to differ from those contained in the forward-looking statements. These factors are described in more detail in the section entitled “Risk Factors” in our Annual Report on Form 10-K filed in the United States. Filed with the Securities and Exchange Commission (SEC) on March 14, 2024. It is also included in other filings that IN8bio may make with the SEC in the future. The forward-looking statements contained in this press release speak only as of the date of this press release, and IN8bio believes that the forward-looking statements contained in this press release speak only as of the date of this press release, and IN8bio may be unable to make any changes to this press release as a result of new information, future events, changes in circumstances, or for any other reason. We expressly disclaim any obligation to update any forward-looking statements contained in. Unless otherwise required by law.
Corporate contact:
IN8bio Co., Ltd.
Glenn Shulman, PharmD, MPH
203.494.7411
gdschulman@IN8bio.com
Investor
Mel Advisors
Lee M. Stern
lstern@meruadvisors.com
media contact
kimberly ha
KKH Advisors
917.291.5744
kimberly.ha@kkhadvisors.com